, Tracking Stock Market Picks
Enter Symbol:
Solta Medical Inc (SLTM) [hlAlert]

down 28.78 %

Thermage, Inc. (SLTM) rated Buy with price target $2.40 by Needham

Posted on: Tuesday,  Feb 24, 2009  8:25 AM ET by Needham

Needham rated Buy Solta Medical Inc (NASDAQ: SLTM) on 02/24/2009. Previously Needham rated Buy Solta Medical Inc (NASDAQ: SLTM) on 02/20/2008.,
when the stock price was $4.10. Since then, Solta Medical Inc has lost 28.78% as of 01/22/2014's recent price of $2.92.
If you would have followed the previous Needham's recommendation on SLTM, you would have lost 28.78% of your investment in 2163 days.

Solta Medical Inc., formerly Thermage, Inc. is engaged in designing, developing, manufacturing and marketing energy-based medical device systems for aesthetic applications. These systems are marketed under the brand names Fraxel and Thermage and are Food & Drug Administration (FDA) cleared for dermatological procedures in the applications, which include: Skin Tightening, the Thermage NXT system offers non-invasive treatment options for skin tightening and contouring, body shaping, and improvement in the appearance of cellulite; Skin Rejuvenation, the Fraxel re:fine and Fraxel re:store systems offer treatments for skin conditions such as fine lines and pigmentation.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/24/2009 8:25 AM Buy
1.09 2.40
as of 12/31/2009
1 Week up  28.71 %
1 Month up  19.81 %
3 Months up  14.53 %
1 YTD down  -14.75 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/11/2008 9:25 AM Buy
2.52 6.00
2/20/2008 9:25 AM Buy
4.10 9.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy